1st Quarter - Report
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC for BOEHRINGER INGELHEIM USA CORPORATION
Firm
Income
—
Expenses
$1,070,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importationi; Non Interference
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| JONATHAN REA MCPHERSON | — |
| ALANNA PORTER TEMME | — |
Consumer Issues/Safety/Products CSP
Food and Drug Administration Safety & Innovationi Act (FDASIA) - Updates/Implementation
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| JONATHAN REA MCPHERSON | — |
| PAUL ROMNESS | — |
| ALANNA PORTER TEMME | — |
Animals ANI
Illegal Compounding of Animal Drugs
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| ALANNA PORTER TEMME | — |
Trade (domestic/foreign) TRD
Transatlantic Trade & Investment Partnership (TTIP)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL ROMNESS | — |
| ALANNA PORTER TEMME | — |
Copyright/Patent/Trademark CPT
Patent Settlements; Patent Trolls (H.R. 3390 - "Innovation Act")
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| JONATHAN REA MCPHERSON | — |
| PAUL ROMNESS | — |
| ALANNA PORTER TEMME | — |
Health Issues HCR
Healthcare Exchanges; Protected Classes; CMS Rule
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| JONATHAN REA MCPHERSON | — |
| ALANNA PORTER TEMME | — |
Medicare/Medicaid MMM
Average Sales Price; Reimbursement
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.